Meeting of the National Vaccine Advisory Committee, 46549-46550 [2019-19201]

Download as PDF Federal Register / Vol. 84, No. 171 / Wednesday, September 4, 2019 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Clinical Care Commission Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The National Clinical Care Commission (the Commission) will conduct a virtual meeting on September 27, 2019. The Commission is charged to evaluate and make recommendations to the U.S. Department of Health and Human Services (HHS) Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases. DATES: The meeting will take place on September 27, 2019, from 2:00 p.m. to approximately 5:30 p.m. Eastern Time (ET). SUMMARY: The meeting will be held online via webinar. To register to attend the meeting, please visit the registration website at https:// kauffmaninc.adobeconnect.com/nccc_ sept_2019/event/event_info.html. FOR FURTHER INFORMATION CONTACT: Clydette Powell, Designated Federal Officer, National Clinical Care Commission, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, Suite LL–100, Rockville, MD 20852, telephone: 240–453–8239, Email: OHQ@ hhs.gov. Additional information may be obtained at https://health.gov/hcq/ national-clinical-care-commission.asp. SUPPLEMENTARY INFORMATION: The National Clinical Care Commission Act (Pub. L. 115–80) requires the HHS Secretary to establish the National Clinical Care Commission. The Commission consists of representatives of specific federal agencies and nonfederal individuals and entities who represent diverse disciplines and views. The Commission will evaluate and make recommendations to the HHS Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that jbell on DSK3GLQ082PROD with NOTICES ADDRESSES: VerDate Sep<11>2014 19:08 Sep 03, 2019 Jkt 247001 result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases. The inaugural meeting of the Commission was held on October 31, 2018, during which non-federal Commission members were sworn-in, and various federal interagency efforts surrounding diabetes program were presented. This virtual meeting will consist of an update on the Data Call to federal agencies and Commission discussion on key topics for secondary research in support of the Report to Congress. The final meeting agenda will be available prior to the meeting at https:// health.gov/hcq/national-clinical-carecommission.asp. Public Participation at Meeting: The Commission invites public comment on issues related to the Commission’s charge. There will be no opportunity for oral comments at this virtual meeting. Written comments are welcome throughout the entire development process of the Commission’s recommendation and may be emailed to OHQ@hhs.gov, or by mail to the following address: Public Commentary, National Clinical Care Commission, 1101 Wootton Parkway, Suite LL–100, Rockville, MD 20852. Written comments should not exceed three pages in length. To virtually attend the Commission meeting, individuals must pre-register at the registration website at https:// kauffmaninc.adobeconnect.com/nccc_ sept_2019/event/event_info.html. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should indicate the special accommodation when registering online or by notifying Jennifer Gillissen at jennifer.gillissen@ kauffmaninc.com by September 20. Authority: The National Clinical Care Commission is required under the National Clinical Care Commission Act (Pub. L. 115–80). The Commission is governed by provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended (5 U.S.C., App.) which sets forth standards for the formation and use of federal advisory committees. Dated: August 20, 2019. Donald Wright, Deputy Assistant Secretary for Health. [FR Doc. 2019–18953 Filed 9–3–19; 8:45 am] BILLING CODE 4150–32–P PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 46549 DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Vaccine Advisory Committee Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, Office of Infectious Disease Policy. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services is hereby giving notice that a meeting is scheduled to be held for the National Vaccine Advisory Committee (NVAC). The meeting will be open to the public; public comment sessions will be held during the meeting. DATES: The meeting will be held on September 17 and 18, 2019. The meeting times and agenda will be posted on the NVAC website at https:// www.hhs.gov/vaccines/nvac/meetings/ index.html as soon as they become available. SUMMARY: U.S. Department of Health and Human Services, Hubert H. Humphrey Building, The Great Hall, 200 Independence Avenue SW, Washington, DC 20201. The meeting can also be accessed through a live webcast on both days of the meeting. For more information, visit https://www.hhs.gov/webforms/nvac/ index.html. Pre-registration is required for members of the public who wish to attend the meeting and who wish to participate in a public comment session. Individuals who wish to attend the meeting and/or participate in a public comment session should register at https://www.hhs.gov/webforms/nvac/ index.html. Participants may also register by emailing nvac@hhs.gov or by calling (202) 795–7697 and providing their name, organization, and email address. ADDRESSES: Ann Aikin, Acting Designated Federal Officer, Office of Infectious Disease Policy, U.S. Department of Health and Human Services, Room L001, Switzer Building, 330 C Street SW, Washington, DC 20201. Phone: (202) 795–7697; email: nvac@hhs.gov. SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of Health and Human Services was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve FOR FURTHER INFORMATION CONTACT: E:\FR\FM\04SEN1.SGM 04SEN1 46550 Federal Register / Vol. 84, No. 171 / Wednesday, September 4, 2019 / Notices jbell on DSK3GLQ082PROD with NOTICES optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program’s responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program. During the September 2019 NVAC meeting, sessions will consist of presentations on immunization equity, immunity, vaccines for small populations and uncommon diseases, and influenza safety monitoring, and evidence-based tools for improving influenza vaccination efforts. Please note that agenda items will be related to the charges of the Committee and are subject to change as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC website: https:// www.hhs.gov/vaccines/nvac/meetings/ index.html. Public attendance at the meeting is limited to the available space. Individuals who plan to attend in person and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Office of Infectious Disease Policy at the address/phone number listed above at least one week prior to the meeting. For those unable to attend in person, a live webcast will be available. More information on registration and accessing the webcast can be found at https://www.hhs.gov/ vaccines/nvac/meetings/. Members of the public will have the opportunity to provide comments at the NVAC meeting during the public comment periods designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is allotted for all those wishing to speak. Individuals are also welcome to submit their written comments. Written comments should not exceed three pages in length. Individuals submitting written comments should email their comments to the Office of Infectious Disease Policy (nvac@hhs.gov) at least five business days prior to the meeting. Dated: August 16, 2019. Ann Aikin, Acting Designated Federal Officer, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2019–19201 Filed 9–3–19; 8:45 am] BILLING CODE 4150–44–P VerDate Sep<11>2014 19:08 Sep 03, 2019 Jkt 247001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group; Microbiology and Infectious Diseases B Subcommittee MID–B Chartered Committee. Date: September 24–25, 2019. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Ellen S. Buczko, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–2676, ebuczko1@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 28, 2019. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–18960 Filed 9–3–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the PO 00000 Frm 00049 Fmt 4703 Sfmt 9990 provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID 2019 Omnibus BAA (HHS–NIH–NIAID–BAA2019–1) Research Area 003: Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria. Date: September 18, 2019. Time: 10:00 a.m. to 4:30 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Reed Solomon Shabman, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 301–761–6433, reed.shabman@ nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44), Clinical Trial Implementation Cooperative Agreement (U01), and Clinical Trial Planning Grant (R34). Date: September 24, 2019. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Yong Gao, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G13B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Rockville, MD 20892–7616, (240) 669–5048, gaoL2@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 28, 2019. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–18959 Filed 9–3–19; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\04SEN1.SGM 04SEN1

Agencies

[Federal Register Volume 84, Number 171 (Wednesday, September 4, 2019)]
[Notices]
[Pages 46549-46550]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-19201]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: Department of Health and Human Services, Office of the 
Secretary, Office of the Assistant Secretary for Health, Office of 
Infectious Disease Policy.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services is hereby giving notice that a 
meeting is scheduled to be held for the National Vaccine Advisory 
Committee (NVAC). The meeting will be open to the public; public 
comment sessions will be held during the meeting.

DATES: The meeting will be held on September 17 and 18, 2019. The 
meeting times and agenda will be posted on the NVAC website at https://www.hhs.gov/vaccines/nvac/meetings/ as soon as they become 
available.

ADDRESSES: U.S. Department of Health and Human Services, Hubert H. 
Humphrey Building, The Great Hall, 200 Independence Avenue SW, 
Washington, DC 20201.
    The meeting can also be accessed through a live webcast on both 
days of the meeting. For more information, visit https://www.hhs.gov/webforms/nvac/.
    Pre-registration is required for members of the public who wish to 
attend the meeting and who wish to participate in a public comment 
session. Individuals who wish to attend the meeting and/or participate 
in a public comment session should register at https://www.hhs.gov/webforms/nvac/. Participants may also register by emailing 
[email protected] or by calling (202) 795-7697 and providing their name, 
organization, and email address.

FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal 
Officer, Office of Infectious Disease Policy, U.S. Department of Health 
and Human Services, Room L001, Switzer Building, 330 C Street SW, 
Washington, DC 20201. Phone: (202) 795-7697; email: [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and 
Human Services was mandated to establish the National Vaccine Program 
to achieve optimal prevention of human infectious diseases through 
immunization and to achieve

[[Page 46550]]

optimal prevention against adverse reactions to vaccines. The NVAC was 
established to provide advice and make recommendations to the Director 
of the National Vaccine Program on matters related to the Program's 
responsibilities. The Assistant Secretary for Health serves as Director 
of the National Vaccine Program.
    During the September 2019 NVAC meeting, sessions will consist of 
presentations on immunization equity, immunity, vaccines for small 
populations and uncommon diseases, and influenza safety monitoring, and 
evidence-based tools for improving influenza vaccination efforts. 
Please note that agenda items will be related to the charges of the 
Committee and are subject to change as priorities dictate. Information 
on the final meeting agenda will be posted prior to the meeting on the 
NVAC website: https://www.hhs.gov/vaccines/nvac/meetings/.
    Public attendance at the meeting is limited to the available space. 
Individuals who plan to attend in person and need special assistance, 
such as sign language interpretation or other reasonable 
accommodations, should notify the Office of Infectious Disease Policy 
at the address/phone number listed above at least one week prior to the 
meeting. For those unable to attend in person, a live webcast will be 
available. More information on registration and accessing the webcast 
can be found at https://www.hhs.gov/vaccines/nvac/meetings/.
    Members of the public will have the opportunity to provide comments 
at the NVAC meeting during the public comment periods designated on the 
agenda. Public comments made during the meeting will be limited to 
three minutes per person to ensure time is allotted for all those 
wishing to speak. Individuals are also welcome to submit their written 
comments. Written comments should not exceed three pages in length. 
Individuals submitting written comments should email their comments to 
the Office of Infectious Disease Policy ([email protected]) at least five 
business days prior to the meeting.

    Dated: August 16, 2019.
Ann Aikin,
Acting Designated Federal Officer, Office of Infectious Disease and 
HIV/AIDS Policy.
[FR Doc. 2019-19201 Filed 9-3-19; 8:45 am]
BILLING CODE 4150-44-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.